8-K

                                  UNITED STATES
                     SECURITIES AND EXCHANGE  COMMISSION
                                 Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)    March 30, 2006

                          MEDISCIENCE TECHNOLOGY CORP.

- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

        NEW JERSEY                      0-7405                   22-1937826

- --------------------------------------------------------------------------------
(State or other jurisdiction          (Commission              (IRS Employer
       of incorporation)              File Number)           Identification No.)


1235 Folkestone Way, P.O. Box 598, Cherry Hill, New Jersey            08034
- --------------------------------------------------------------------------------
        (Address of principal executive offices)                    (Zip Code)

Registrant's telephone number, including area code (215) 485 0362

         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2- below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17CFR240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13 e-4(c) under the
    Exchange Act (17 CFR 240.13 e-4(c))



Item  8.01. Other Events.

On April 3, 2006 Mediscience Technology, Corp. (OTCBB:MDSC.OB) announced The
Food and Drug Administration on March 29, 2006 approved as a "Non-significant
risk device study the Company's multi-center pilot study to establish the safety
and parameters of efficacy of its proprietary Optical Biopsy Device (CD-R) for
cancer detection of the cervix preliminary to a pivotal study" expected to bring
this molecular algorithmic specific technology to market. This disclosure is
intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7
and 7.0 as well as all applicable and presently effective Sarbanes-Oxley
disclosure requirements under Regulation G.


Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release of Mediscience Technology Corp. dated April 3, 2006



                                   SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized on April 3, 2006

                                             MEDICSCIENCE TECHNOLOGY CORPORATION

                                             By:  Peter Katevatis
                                                  ------------------------------
                                             Name: Peter Katevatis
                                             Title: Chairman of the Board and
                                                    Chief Executive Officer


                                                                               2



                                  Exhibit Index

Exhibit No.   Description
- -----------   ------------------------------------------------------------------

99.1          Press Release of Mediscience Technology Corp. dated  April 3, 2006







                                                                               3

EX-99.1

                                                                    Exhibit 99.1

        FDA Approves Mediscience Optical Biopsy Device multi-center pilot
               study for molecular cancer detection of the cervix

CHERRY HILL, N.J.--(BUSINESS WIRE)--April 3, 2006 Mediscience Technology, Corp.
(OTCBB:MDSC.OB) announced today: The Food and Drug Administration on March 29,
2006 approved as a "Non-significant risk device study the Company's multi-center
pilot study to establish the safety and parameters of efficacy of its
proprietary Optical Biopsy Device (CD-R) for cancer detection of the cervix
preliminary to a pivotal study" expected to bring this molecular algorithmic
specific technology to market.

Dr Robert Schiff of Schiff & Company/ Regulatory Affairs advised "The FDA has
notified Mediscience that the device (CD-R) is a non-significant risk device. We
can therefore commence the Pilot study at any time observing the regulations
governing patient consent and institutional IRB approval. The FDA has also given
us comments and suggestions which will assist Mediscience in its clinical
studies."

Peter Katevatis Chairman/ CEO "The main objectives of this pilot study are to
determine efficacy; the clinical sensitivity and clinical specificity (ability
for the device to distinguish between tissues that are normal, benign,
precancerous low grade, precancerous high grade, CIS and cancer) by comparing
the device real-time results to the PAP test and biopsy; and assess any adverse
events based on Good Clinical Practices. Frequency, type and intensity of
clinical adverse events will also be evaluated. Assuming the results of this
initial efficacy and safety study are satisfactory, in the detection of cervical
cancer precursors i.e. (pre-cancerous cells), indications of possible cancer
development the Company will continue into its pivotal study where the principal
endpoint will be proof of effectiveness in a statistically significant sample of
subjects.

Dr. Robert Alfano (pioneer in optical biopsy, co-founder and advisor to
Mediscience Technology and President of Alfanix LTD) " This FDA approval
advances Mediscience to the next level towards commercialization and is a major
step in advancing diagnostic medicine using fluorescence light. Alfanix plans to
help Mediscience with it's CD-R platform technology in the medical cancer areas
and possibly expanding the market into Latin America."

Mediscience Technology Corporation is engaged in the design and development of
fluorescence-based optical biopsy platform system that uses the properties of
light and its molecular interaction with tissue to aid in the diagnosis of
physiological change and cancer.

The Mediscience IP technology platform is based on imaging native fluorescence
from the surface of an optically excited tissue and offers paradigm shift
potential as a noninvasive, in-vivo cancer diagnostic because of the unique
ability to detect/distinguish abnormalities in molecular tissue composition
and/or structure. Further, the development of a Mediscience cost effective, high
resolution commercial imaging system for real-time

                                                                               4


in-vivo diagnostics has the potential to vastly improve upon current standards
of diagnostic sensitivity and specificity. (e.g. Cervical cancer a highly
preventable cancer with early detection and removal of pre-cancerous cervical
lesions)

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics
Development Company LLC, are engaged in the design, development and
commercialization of medical devices that detect cancer and physiological change
using frequencies of light that are emitted, scattered and absorbed to
distinguish malignant, Pre-cancerous or benign tissues from normal tissues.
Mediscience's exclusive protected noninvasive technology combines the advantages
of real-time results with enhanced diagnostic sensitivity and specificity
compared with other methods of cancer detection.

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp
www.cunyphotonics.com
www.MEDISCIENCETECH.com
Mediscience 8-K filing dated April 4, 2006
New England Journal of Medicine 7-29-04 (capsule endoscopic technology)
CITIGROUP/Smith Barney Analyst Report 10-1-2004 by Peter Bye. Page
20 (Mediscience/Infotonics)
Alfanix LTD Dr. Robert Alfano 917 969 2209 web: info@alfanix.com

                                 INVESTOR NOTICE

      Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and uncertainties in
the parties/company's business that may cause actual results to differ
materially from those anticipated by the statements made herein. Such risks and
uncertainties include among other things, the availability of financing, the
parties/ company's ability to implement its long-range business plan for the
joint or independent development of various applications of its technology/ IP;
the company's ability to enter into future agreements with any necessary
marketing and/or distribution partners; the impact of competition, the obtaining
and maintenance of any necessary US regulatory i.e. FDA clearances applicable to
applications of the company's technology; and management of growth and other
risked and uncertainties that may be detailed from time to time in the
parties/company's reports filed with the Securities and Exchange Commission.
This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD,
disclosure and Section 7 and 7.0 as well as all applicable and presently
effective Sarbanes-Oxley disclosure requirements under Regulation G.

      CONTACT: Mediscience ---Peter Katevatis Chairman/CEO 215 485 0362 or
      metpk@aol.com Dr. Robert Alfano 917 969 2209 web: info@alfanix.com


                                                                               5